Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden

A Multicenter, Open Label Study Assessing the Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04461795

Enrollment

Registered

2020-07-08

Start date

2020-12-01

Completion date

2022-01-10

Last updated

2022-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine

Brief summary

This study is being conducted to evaluate the efficacy and safety of AJOVY (fremanezumab-vfrm) on interictal migraine related burden in adults.

Detailed description

This is a single group, multicenter, open-label study with a study population of patients who meet International Classification of Headache Disorders 3rd edition (ICHD-III) criteria for migraine with or without aura and have 4 to 22 migraine days per month. This is a single-group supportive care study with one arm and no masking. A maximum of 40 participants will be enrolled to study intervention. All participants in this single-group study will complete a 4-week run-in period. After the run-in period, eligible participants will be enrolled to study intervention and enter a 12-week treatment period.

Interventions

DRUGFremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]

225 MG/1.5 ML Subcutaneous Solution

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

1. willing to participate and sign informed consent; 2. ability to read and understand informed consent and study procedures, including able to use the electronic Daily Headache Diary; 3. in good general health based on investigator's judgment; 4. must be between 18 to 65 years of age, inclusive, at time of Visit 2; 5. have migraine with and/or without aura meeting the diagnostic criteria listed in the International Classification of Headache Disorders 3rd edition (ICHD-III; Appendix 5); 6. verification of headache frequency through prospectively collected baseline information during the 28-day screening/baseline phase reporting 4-22 migraine days and no more than 22 total headache days; 7. onset of migraine before age 50; 8. able to differentiate migraine from other primary headache types allowed in the study (e.g., tension-type headache); 9. stable history of migraine at least 3 months prior to screening with at least some discreet headache free periods; 10. not currently taking a migraine preventive OR has been taking a stable dose of a preventive for at least 90 days prior to screening and agrees to not start, stop, or change medication and/or dosage during the study period; \* \* participants on migraine preventive should have stable headache pattern 11. women may be included only if they have a negative pregnancy test at screening and baseline, are sterile, or postmenopausal. Women of childbearing potential (WOCBP) engaging in potentially procreative intercourse must use highly effective birth control methods for the duration of the study (i.e., starting at screening). Definitions of WOCBP, sterile and postmenopausal women, male contraception, and highly effective and acceptable birth control methods are to be determined based on investigator's judgment; 12. demonstrated compliance with the electronic Daily Headache Diary during the 28-day screening/baseline phase as defined by entry of headache data on a minimum of 23 days; 13. is willing to wear activity/sleep tracker throughout the duration of the trial; 14. has a smartphone and willing to install activity tracker app on phone.

Exclusion criteria

1. unable to understand the study requirements, the informed consent, or complete headache records as required per protocol; 2. pregnant, actively trying to become pregnant, or breast-feeding; 3. history of substance abuse and/or dependence that would interfere study conduction, in the opinion of the Investigator; 4. history of impaired renal function that, in the investigator's opinion, contraindicates participation in this study; 5. suffers from a serious illness, or an unstable medical condition, one that could require hospitalization, increase the risk of adverse events, or compromise data integrity (ie, likely require changes in con meds or lead to other medical investigations or treatments during the study). 6. a psychiatric condition, in the opinion of the investigator, that may affect the interpretation of efficacy and safety data or contraindicates the participant's participation in the study; 7. received nerve blocks or trigger point injections in the previous 8 weeks or plans to receive them during the study; 8. prior exposure in the last 6 months, or 5 half-lives, to biologics or drugs specifically targeting the calcitonin gene-related peptide (CGRP) pathway; 9. has failed more than 3 classes of medications for the prevention of migraine or \>6 migraine preventive medications of any type due to lack of efficacy; 10. received any investigational agents within 30 days prior to Visit 1 (6 months for any investigational biological products unless previous study blind has been broken and subject was known to have received placebo); 11. plans to participate in another clinical study at any time during this study; 12. history of medication overuse of opioids or butalbital, as defined by opioid or butalbital use ≥10 days/month in each of the previous 3 months or during run-in period; Medication Overuse Headache (MOH) with other medication types will be allowed but must be documented; 13. unstable medication use for migraine prevention (changes in the last 3 months); 14. clinically relevant lab results at screening as determined by the investigator; 15. clinically relevant or significant ECG abnormalities as determined by the investigator, including ECG with QT interval corrected for heart rate (QTc) using Fridericia's correction formula (QTcF) \> 500 msec; 16. history of any of the following cardiovascular conditions: 1. Moderate to severe congestive heart failure (New York Heart Association class III or IV); 2. Recent (within past 6 months) cerebrovascular accident, myocardial infarction, coronary stenting; 3. Uncontrolled hypertension as defined by a confirmed systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg. 17. Subjects known to have active HIV or untreated Hepatitis C infection; 18. score of \> 0 on question 9 on Patient Health Questionnaire (PHQ-9) at any visit; 19. have any other condition, that in the judgment of the investigator, would make the participant unsuitable for inclusion, or would interfere with the participant participating in or completing the study.

Design outcomes

Primary

Measure	Time frame	Description
Change in Migraine Interictal Burden Scale (MIBS-4) Scores From Baseline to Weeks 4, 8, and 12.	Baseline to Weeks 4, 8, and 12	The Migraine Interictal Burden Scale (MIBS-4) is a 4-item, self-administered questionnaire which measures interictal migraine-related burden in 4 domains: impairment in work or school, impairment in family and social life, difficulty making plans or commitments, and emotional/affective and cognitive distress. Possible scores range from 0 (No interictal burden) to 12 (Severe interictal burden). Change = (Applicable Treatment Month Score - Baseline Score)

Secondary

Measure	Time frame	Description
Change in Neuro-QoL Sleep Disturbance Short Form (SDSF) Scores From Baseline to Weeks 4, 8, and 12.	Baseline to Weeks 4, 8, and 12	The Neuro-QoL Sleep Disturbance Short Form (SDSF) is an 8-item, self-administered questionnaire which measures quality of sleep including difficulties and perception of sleep satisfaction. Possible scores range from 8 to 40, with higher scores indicating worse sleep habits. Change = (Applicable Treatment Month Score - Baseline Score)
Change in General Self-Efficacy - Short Form (GSE-SF) Scores From Baseline to Weeks 4, 8, and 12.	Baseline to Weeks 4, 8, and 12	The General Self-Efficacy - Short Form (GSE-SF) is a 4 item, self-administered questionnaire where the participant is asked to rate their confidence in managing situations, problems, and events. Scores range from 4-20. Higher scores indicate the participant has more self-efficacy managing difficult situations. Change = (Applicable Treatment Month Score - Baseline Score)
Change in Number of Monthly Migraine Days From Baseline to Weeks 4, 8, and 12.	Baseline to Weeks 4, 8, and 12	Comparison of the mean change from baseline in the frequency of migraine headache days per 28-day period ending with the cessation of treatment month 3. A migraine headache day will be defined as a calendar day (00:00 to 23:59) with 4 or more hours of migraine headache, fulfilling International Classification of Headache Disorders-3 criteria, and/or any headache of any duration with the use of migraine-specific acute medications(s) (i.e. ergot alkaloids, ergot combinations, opioids, triptans, combination analgesics \[simple analgesics combined with opioids or barbiturate with or without caffeine\]). Change = (Applicable Treatment Month Score - Baseline Score)
Change in Work Productivity and Activity Impairment - Migraine (WPAI-M) Activity Impairment Scores From Baseline to Weeks 4, 8, and 12.	Baseline to Weeks 4, 8, and 12	The Work Productivity and Activity Impairment - Migraine (WPAI-M) is a 6-item self-administered questionnaire that measures work productivity and the amount of time missed from work due to migraine. Scores are based on a percentage, so the range of scores is 0-100%, with higher scores indicating greater impairment and less productivity. Change = (Applicable Treatment Month Score - Baseline Score)
Change in Brief Measure of Worry Severity (BMWS) Scores From Baseline to Weeks 4, 8, and 12.	Baseline to Weeks 4, 8, and 12	The Brief Measure of Worry Severity (BMWS) is a 8-item, self-administered questionnaire that measures various components of dysfunctional worry. Score range from 0-24 with higher scores indicating more worry within the participant. Change = (Applicable Treatment Month Score - Baseline Score)
Change in Patient-Reported Outcomes Measurement Information System 29 (PROMIS 29) Global Pain Intensity Scores From Baseline to Weeks 4, 8, and 12.	Baseline to Weeks 4, 8, and 12	The Patient-Reported Outcomes Measurement Information System 29 (PROMIS 29) has 7 domains each with 4 questions, and then one global Pain Intensity item. The domains include: Physical Function, Anxiety, Depression, Fatigue, Sleep Disturbance, Ability to Participate in Social Roles and Activities, and Pain Interference. The global item domain is Pain Intensity. Each PROMIS domain can range from a score of 4-20, higher scores equals more of the concept being measured (e.g., more Fatigue, more Physical Function). The outcome measure for this endpoint is the change in the global item (Pain Intensity) from baseline. The Global Pain Intensity item can range from 0-10, with higher scores indicating more severe pain intensity. Change = (Applicable Treatment Month Score - Baseline Score)

Countries

United States

Participant flow

Participants by arm

Arm	Count
AJOVY (Fremanezumab-vfrm) Participants received 225 mg/1.5 mL solution via single-dose prefilled syringe administered subcutaneously once every 4 weeks in the abdomen, thigh, or upper arm for 12 weeks. Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution \[AJOVY\]: 225 MG/1.5 ML Subcutaneous Solution	40
Total	40

Withdrawals & dropouts

Period	Reason	FG000
Overall Study	Lost to Follow-up	2
Overall Study	Protocol Specified Withdrawal Criterion Met	1
Overall Study	Withdrawal by Subject	2

Baseline characteristics

Characteristic	AJOVY (Fremanezumab-vfrm)
Age, Continuous	44.38 years STANDARD_DEVIATION 11.2
Ethnicity (NIH/OMB) Hispanic or Latino	0 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	40 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) American Indian or Alaska Native	0 Participants
Race (NIH/OMB) Asian	0 Participants
Race (NIH/OMB) Black or African American	5 Participants
Race (NIH/OMB) More than one race	0 Participants
Race (NIH/OMB) Native Hawaiian or Other Pacific Islander	0 Participants
Race (NIH/OMB) Unknown or Not Reported	0 Participants
Race (NIH/OMB) White	35 Participants
Region of Enrollment United States	40 participants
Sex: Female, Male Female	36 Participants
Sex: Female, Male Male	4 Participants

Adverse events

Event type	EG000 affected / at risk
deaths Total, all-cause mortality	0 / 40
other Total, other adverse events	14 / 40
serious Total, serious adverse events	0 / 40

Outcome results

Primary

Change in Migraine Interictal Burden Scale (MIBS-4) Scores From Baseline to Weeks 4, 8, and 12.

The Migraine Interictal Burden Scale (MIBS-4) is a 4-item, self-administered questionnaire which measures interictal migraine-related burden in 4 domains: impairment in work or school, impairment in family and social life, difficulty making plans or commitments, and emotional/affective and cognitive distress. Possible scores range from 0 (No interictal burden) to 12 (Severe interictal burden). Change = (Applicable Treatment Month Score - Baseline Score)